Table 1.
Patient demographics.
| Patient no. | Sex | Age (y) | Clinical statement | No of PET lesions in the brain | Localization | FCH SUVmax | Pathology | Outcome (months) | Corticosteroid use |
|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 60 | Melanoma | 2 | L frontal | 6.8 | positive | AWD (68) | No |
| 2 | M | 46 | Lung cancer | 2 | L frontal | 10.1 | positive | unknown† | No |
| 3 | F | 45 | Breast cancer | 1 | L posterior parietal | 6.7 | positive | deceased (36) | No |
| 4 | M | 50 | Lung cancer | 1 | Paramedian R parietal | 1.7 | negative | AWD (57) | No |
| 5 | F | 66 | Ovarian cancer | 1 | Cerebellum | 8.1 | positive | deceased (26) | No |
| 6 | F | 55 | Endocrine carcinoma | 3 | Anterior R frontal, R occipital, L basal ganglia | 8.2 | positive | deceased (7) | Fluticasone |
| 7 | M | 70 | Colorectal cancer | 3 | R occipital | 12.7 | positive | deceased (4) | No |
| 8 | M | 62 | Lung cancer | 1 | L frontal | 2.1 | negative | AWD (33) | No |
| 9 | M | 76 | Renal carcinoma | 1 | L frontoparietal | 4.8 | positive | deceased (2) | Prednisone |
| 10 | M | 71 | Melanoma | 2 | L posterior parietal, R temporal | 5.3 | N/A* | AWD (43) | No |
| 11 | F | 24 | Leiomyosarcoma | 2 | R temporal, L parietal | 9.0 | positive | deceased (27) | Dexamethasone |
| 12 | M | 22 | Testicular cancer | 1 | R frontal | 3.7 | N/A* | AWD (40) | Dexamethasone |
| 13 | F | 74 | Melanoma | 1 | R temporal | 0.7 | positive‡ | AWD (64) | No |
| 14 | F | 49 | Breast Cancer | 1 | L parietal | 4.2 | positive§ | deceased (10) | No |
PET - Positron emission tomography; FCH - 18F-Fluorocholine; AWD - alive with disease;
*
surgical samples were not acquired.
†
- international patient.
‡
- Kinetic modeling not be performed (absence of attenuation-corrected dynamic data).
§
- Kinetic modeling not performed (slow influx of activity through the major vessels into the head, possibly due to less than optimal tracer bolus).